Shrunken Pore Syndrome is associated with a sharp rise in mortality in patients undergoing elective coronary artery bypass grafting

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 76, Issue 1, 2016, Pages 74-81

  Dardashti, Alain ^a   Nozohoor, Shahab ^a   Grubb, Anders ^a   Bjursten, Henrik ^a  

^a LUND UNIVERSITY   (Sweden)

Author keywords

Coronary artery bypass; creatinine; cystatin C; glomerular filtration rate; mortality determinants

Indexed keywords

CREATININE; CYSTATIN C;

AGED; ARTICLE; CARDIOVASCULAR MORTALITY; COHORT ANALYSIS; COLORIMETRY; CORONARY ARTERY BYPASS GRAFT; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; ELECTIVE SURGERY; FEMALE; FOLLOW UP; GLOMERULAR DYSFUNCTION; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; MUSCLE ATROPHY; POST TREATMENT SURVIVAL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SHRUNKEN PORE SYNDROME; SURGICAL MORTALITY; SURVIVAL; SURVIVAL RATE; SYNDROME; ADVERSE EFFECTS; BLOOD; GLOMERULUS; GLOMERULUS FILTRATION RATE; KAPLAN MEIER METHOD; KIDNEY DISEASES; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY;

AGED; CORONARY ARTERY BYPASS; CREATININE; CYSTATIN C; ELECTIVE SURGICAL PROCEDURES; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KAPLAN-MEIER ESTIMATE; KIDNEY DISEASES; KIDNEY GLOMERULUS; MALE; MIDDLE AGED; SYNDROME;

EID: 84947733556     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365513.2015.1099724     Document Type: Article

References (27)

1. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005;352:2049-60.
2. Peralta CA, Shlipak MG, Judd S, Cushman M, McClellan W, Zakal NA, Safford MM, Zhan X, Muntner P. Detection of chronic kidney disease with creatinine, cystatin C, and urine albumin-to-creatinine ratio and association with progression to end-stage renal disease and mortality. JAMA 2011;305:1545-52.
3. Shlipak MG, Matsushita K, ärnlöv J, Inker LA, Katz R, Polkinghorne KR, Rothenbacher D, Sarnak MJ, Astor BC, Coresh J, Levey S, Gansevoort RT. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med 2013;369:932-43.
4. Knight EL, Verhave JC, Spiegelman D, Hillege HL, deZeeuw D, Curhan GC, deJong PE. Factors influencing cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004;65:1416-21.
5. Grubb A, Björk J, Nyman U, Pollak J, Bengzon J, östner G, Lindström V. Cystatin C, a marker for successful aging and glomerular filtration rate, is not influenced by inflammation. Scand J Clin Lab Invest 2011;71:145-19.
6. Grubb A, Lindström V, Kristensen K, Christensson A, Wide-Swensson D, Strevens H, Schmidt C, Blirup-Jensen S. Filtration quality: A new measure of renal disease. Clin Chem Lab Med 2007;45(Suppl. ):S273-4.
7. Strevens H, Wide-Swensson D, Torffvit O, Grubb A. Serum cystatin C for assessment of glomerular filtration rate in pregnant and non-pregnant women. Indications of altered filtration process in pregnancy. Scand J Clin Lab Invest 2002;62:141-7.
8. Kristensen K, Lindström V, Schmidt C, Blirup-Jensen S, Grubb A, Wide-Swensson D, Strevens H. Temporal changes of the plasma levels of cystatin C, beta-trace protein, b2-microglobulin, urate and creatinine during pregnancy indicate continuous alterations in the renal filtration process. Scand J Clin Lab Invest 2007;67:612-8.
9. Strevens H, Wide-Swensson D, Grubb A. Serum cystatin C is a better marker for preeclampsia than serum creatinine or serum urate. Scand J Clin Lab Invest 2001;61:575-80.
10. Kristensen K, Wide-Swensson D, Schmidt C, Blirup-Jensen S, Lindström V, Strevens H, Grubb A. Cystatin C, beta-2-microglobulin and beta-trace protein in pre-eclampsia. Acta Obstet Gynecol Scand 2007;86:921-6.
11. Grubb A, Lindström V, Jonsson M, Bäck SE, Ahlund T, Rippe B, Christensson A. Reduction in glomerular pore size is not restricted to pregnant women. Evidence for a new syndrome: ''Shrunken pore syndrome''. Scand J Clin Lab Invest 2015;75:333-40.
12. Grubb A, Horio M, Hansson LO, Björk J, Nyman U, Flodin M, Larssson A, Bökenkamp A, Yasuda Y, Blufpand H, Lindström V, Zegers I, Althaus H, Blirup-Jensen S, Itoh Y, Sjöström P, Nordin G, Christensson A, Klima H, Sunde K, Hjort-Christensen P, Armbruster D, Ferrrero C. Generation of a new cystatin C-based estimating equation for glomerular filtration rate using seven assays standardized to the international calibrator. Clin Chem 2014;60:974-86.
13. Nyman U, Grubb A, Larsson A, Hansson L-O, Flodin M, Nordin G, Lindström V, Björk J. The revised Lund-MalmöGFR estimating equation outperforms MDRD and CKD-EPI across GFR, age and BMI intervals in a large Swedish population. Clin Chem Lab Med 2014;52:815-24.
14. Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, Kusek JW, Manzi J, Van Lente F, Zhang YP, Coresh J, Levey AS. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012;367:20-9.
15. Nyman U, Grubb A, Sterner G, Björk J. Different equations to combine creatinine and cystatin C to predict GFR. Arithmetic mean of existing equations performs as well as complex combinations. Scand J Clin Lab Invest 2009;69:619-27.
16. Grubb, A. Non-invasive estimation of glomerular filtration rate (GFR). The Lund model: simultaneous use of cystatin C-and creatinine-based GFR-prediction equations, clinical data and an internal quality check. Scand J Clin Lab Invest 2010;70:65-70.
17. Grubb A, Nyman U, Björk, J. Improved estimation of glomerular filtration rate (GFR) by comparison of eGFRcystatin C and eGFRcreatinine. Scand J Clin Lab Invest 2012;72:73-7.
18. Dardashti A, Ederoth P, Algotsson L, Brondén B, Bjursten H. Incidence, dynamics, and prognostic value of acute kidney injury for death after cardiac surgery. J Thorac Cardiovasc Surg 2014;147:800-7.
19. Arturson G, Groth T, Grotte G. Human glomerular membrane porosity and filtration pressure: dextran clearance data analysed by theoretical models. Clin Sci 1971;40:137-58.
20. Carrie BJ, Myers BD. Proteinuria and functional characteristics of the glomerular barrier in diabetic nephropathy. Kidney Int 1980;17:669-76.
21. Scandling JD, Myers BD. Glomerular size-selectivity and microalbuminuria in early diabetic glomerular disease. Kidney Int 1992;41:840-6.
22. Deckert T, Kofoed-Enevoldsen A, Vidal P, Nørgaard K, Andreasen HB, Feldt-Rasmussen B. Size-and charge selectivity of glomerular filtration in Type 1 (insulindependent) diabetic patients with and without albuminuria. Diabetologia 1993;36:244-51.
23. Roberts M, Lindheimer MD, Davison JM. Altered glomerular permselectivity to neutral dextrans and heteroporous membrane modeling in human pregnancy. Am J Physiol 1996;270:F338-43.
24. Blouch K, Deen WM, Fauvel JP, Bialek J, Derby G, Myers BD. Molecular configuration and glomerular size selectivity in healthy and nephrotic humans. Am J Physiol 1997;273:F430-7.
25. Zayas CF, Guasch A. Early glomerular dysfunction in human renal allografts. Kidney Int 2001;60:1938-47.
26. Oberbauer R, Nenov V, Weidekamm C, Haas M, Szekeres T, Mayer G. Reduction in mean glomerular pore size coincides with the development of large shunt pores in patients with diabetic nephropathy. Exp Nephrol 2001;9:49-53.
27. Sasser JM, Murphy SR, Granger JP. Emerging drugs for preeclampsia-the endothelium as a target. Expert Opin Emerg Drugs 2015; [Epub ahead of print].